KRRO

Korro Bio, Inc. (NASDAQ:KRRO) is a biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. The company went public in October 2019 and specializes in developing genetic medicines through RNA editing technology. Korro Bio focuses on creating treatments for both rare genetic diseases and more common conditions by correcting disease-causing mutations at the RNA level rather than permanently altering DNA. The company is currently in the clinical development stage with multiple programs targeting various therapeutic areas.